A Phase 3 interventional study of Norfloxacin and Itopride in Spontaneous Bacterial Peritonitis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2019-11-13.
Sponsored by Tanta University · Phase 3, Interventional, and Prevention
Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Comparative Study of Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
167 studies on the registry are indexed under Peritonitis; 23 are open to participants now.
This study's planned enrollment of 80 is close to the median of 79 across 106 interventional studies indexed under Peritonitis.
Browse Peritonitis studies →Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Norfloxacin 400 mg daily
Drug: Norfloxacin
Norfloxacin 400 mg daily and Itopride 50 mg three times daily.
Drug: Norfloxacin · Drug: Itopride
Norfloxacin 400 mg daily
Also known as: Epinor
Itopride 50 mg three times daily
Also known as: Ganaton
Number of bouts of recurrence during treatment.
The recurrence of infection during treatment.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itopride